FY2024 Earnings Forecast for AURA Issued By Lifesci Capital

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Lifesci Capital issued their FY2024 EPS estimates for shares of Aura Biosciences in a research note issued on Tuesday, January 21st. Lifesci Capital analyst O. Mccammon expects that the company will earn ($1.65) per share for the year. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.67) per share. Lifesci Capital also issued estimates for Aura Biosciences' Q4 2024 earnings at ($0.42) EPS and FY2025 earnings at ($2.52) EPS.

Other research analysts have also recently issued research reports about the stock. Scotiabank boosted their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a "sector outperform" rating in a report on Friday, October 18th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. BTIG Research raised their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, October 18th. Finally, Cowen reaffirmed a "buy" rating on shares of Aura Biosciences in a research note on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $23.00.

Aura Biosciences Stock Performance

Shares of NASDAQ AURA traded down $0.21 during mid-day trading on Friday, reaching $7.89. 119,197 shares of the company's stock were exchanged, compared to its average volume of 131,066. The company's 50-day moving average is $8.38 and its 200-day moving average is $8.91. The firm has a market capitalization of $394.11 million, a price-to-earnings ratio of -4.56 and a beta of 0.30. Aura Biosciences has a 52-week low of $6.63 and a 52-week high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.02.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aura Biosciences in the 4th quarter valued at $87,000. American Century Companies Inc. acquired a new position in Aura Biosciences in the 2nd quarter valued at approximately $119,000. SG Americas Securities LLC acquired a new position in Aura Biosciences during the 3rd quarter worth about $169,000. JPMorgan Chase & Co. raised its stake in Aura Biosciences by 107.5% during the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company's stock worth $477,000 after buying an additional 27,718 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Aura Biosciences by 39.6% during the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company's stock worth $480,000 after buying an additional 18,011 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now directly owns 151,693 shares in the company, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Los Pinos Elisabet De sold 9,200 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the sale, the insider now owns 320,647 shares in the company, valued at $3,443,748.78. This trade represents a 2.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,531 shares of company stock valued at $345,454 in the last three months. 5.40% of the stock is currently owned by company insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.